Finally, given that previously used siRNA or other knockdown/knockout strategies will unbiasedly target both normal STIM1 and STIM1β, it remains imperative to revisit some earlier studies to sort out the contribution of each splice variant to cancer and other pathological conditions associated with augmented STIM1 signaling. This evidence concerns the gene STIM1 and cancer.